At the Forefront of the Revolution For Cancer Research
Cleveland Clinic is at the forefront of innovative translational and clinical research that will lead to new cancer drugs and therapies. Through our cancer research, we have identified new molecules with anti-tumor effects, developed collaborative ties with biotechnology companies, begun training more young scientists, and expanded our base of financial support.
This ongoing effort by Cleveland Clinic research and support staff has provided new and better cancer treatments in order to provide patients with the very best cancer care.
National Cancer Institute - Designated Cancer Center
As part of the Case Comprehensive Cancer Center, a National Cancer Institute-designated cancer center, Cleveland Clinic demonstrates expertise in laboratory, clinical and behavioral and population-based research.
Research News & Articles
First-of-its-Kind phase 2 study shows oral therapy is viable treatment option for elderly AML patients with a specific genetic abnormality.
Patients who develop high blood pressure while being treated for advanced kidney cancer with the drug sunitinib respond better to treatment, maintain longer progression-free survival, and survive longer, according to a Cleveland Clinic-led study.
Cleveland Clinic researchers announced the results of a study that suggests prostate cancer screening improves quality of life and decreases a patient's risk of developing metastatic disease.
A first-of-its-kind vaccine to prevent breast cancer has shown overwhelmingly favorable results in animal models, according to a study by researchers at Cleveland Clinic's Lerner Research Institute.
Researchers from the Cleveland Clinic and the University of California, San Francisco revealed that the virus XMRV has been linked to prostate cancer and chronic fatigue syndrome. Additional research is under way to determine if XMRV is a cause of human diseases or just a passenger virus.
Taussig Cancer Institute has been awarded more than $2 million from the American Recovery and Reinvestment Act (ARRA) for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, part of the National Institutes of Health, awarded the grant, which will create 17 new jobs.
In September 2009, Jaroslaw Maciejewski, MD, PhD, Chairman of the Department of Translational Hematology and Oncology Research, received a five-year, $1.9 million grant from the National Institutes of Health (NIH) to help fund his research of viruses as a potential cause of certain types of bone marrow cancers and other blood disorders.
Cleveland Clinic researchers today presented findings that suggest cancer could be treated in a novel way that is much less toxic.
The researchers found that they could alter an existing chemotherapy drug to stop the growth of cancer cells and encourage the growth of healthy cells. Current treatments kill both cancer cells and healthy cells, which leads to numerous side effects.
Cleveland Clinic researchers have published the results of the first study to track the treatment patterns used by physicians who care for patients with myelodysplastic syndromes (MDS). MDS, which was once considered an orphan disease, is now considered a cancer mainly affecting the elderly. The Surveillance, Epidemiology and End Results (SEER) database has tracked MDS for seven years, but little has been known about how MDS patients have been treated for their disease, or the characteristics of these patients, until now.
Research Links
Search our database for a listing of clinical trials available at Taussig Cancer Institute.
To schedule an appointment or ask a nurse your cancer questions.
Every day, Cleveland Clinic researchers and clinicians work in laboratories and at bedsides to improve the lives of cancer patients.
